114 results
Page 3 of 6
8-K
4neo57d5rw0c
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
424B5
qcxs4x9 i1wdx
12 Aug 22
Prospectus supplement for primary offering
8:31am
8-K
mh8ed v7ln3y4qot
25 May 22
Regulation FD Disclosure
7:02am
8-K
EX-99.1
8261arv
25 May 22
Regulation FD Disclosure
7:02am
8-K
EX-1.1
jm6m1009i sicbszw8
13 Apr 22
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
4:26pm
424B5
veug6c7 ak2
13 Apr 22
Prospectus supplement for primary offering
4:22pm
8-K
EX-99.1
6u0j2
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
EX-99.2
0tt yevio3ibthh95yj
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
xc0000t
28 Feb 22
Entry into a Material Definitive Agreement
8:30am
424B5
bvbr1bgasd8nzu
21 Oct 21
Prospectus supplement for primary offering
4:26pm
8-K
EX-1.1
bpp5 6erpdv
21 Oct 21
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:24pm
424B5
6cl2b1g
20 Oct 21
Prospectus supplement for primary offering
4:15pm
8-K
EX-99.1
luirdjejnd33
15 Sep 21
Regulation FD Disclosure
4:05pm
S-3ASR
68ipdbbx1eb7
10 Aug 21
Automatic shelf registration
5:25pm